ChiCTR2400092725 版本V1.0 版本创建时间2024/11/21 18:06:51 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400092725 

最近更新日期:

Date of Last Refreshed on:

2024-11-21 18:06:34 

注册时间:

Date of Registration:

2024-11-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

颅脑动脉瘤介入栓塞手术患者术后发生AKI的危险因素的相关性研究—一项回顾性队列分析

Public title:

A Correlation Study on Risk Factors for Postoperative AKI in Patients Undergoing Endovascular Embolization of Cerebral Aneurysms - A Retrospective Cohort Analysis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

颅脑动脉瘤介入栓塞手术患者术后发生AKI的危险因素的相关性研究—一项回顾性队列分析

Scientific title:

A Correlation Study on Risk Factors for Postoperative AKI in Patients Undergoing Endovascular Embolization of Cerebral Aneurysms - A Retrospective Cohort Analysis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘娟 

研究负责人:

刘娟 

Applicant:

Juan Liu 

Study leader:

Juan Liu 

申请注册联系人电话:

Applicant telephone:

+86 138 1402 6975

研究负责人电话:

Study leader's telephone:

+86 138 1402 6975

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

544607917@qq.com

研究负责人电子邮件:

Study leader's E-mail:

544607917@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

南京市鼓楼区广州路264号

研究负责人通讯地址:

南京市鼓楼区广州路264号

Applicant address:

264 Guangzhou Road, Gulou District, Nanjing City

Study leader's address:

264 Guangzhou Road, Gulou District, Nanjing City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京脑科医院

Applicant's institution:

Nanjing Brain Hospital

研究负责人所在单位:

南京脑科医院

Affiliation of the Leader:

Nanjing Brain Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-KY079-01快

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京脑科医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Nanjing Brain Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-09-02 00:00:00

伦理委员会联系人:

王小珊

Contact Name of the ethic committee:

Xiaoshan Wang

伦理委员会联系地址:

南京市鼓楼区广州路264号

Contact Address of the ethic committee:

264 Guangzhou Road, Gulou District, Nanjing City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 137 7055 7940

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京脑科医院

Primary sponsor:

Nanjing Brain Hospital

研究实施负责(组长)单位地址:

南京市鼓楼区广州路264号

Primary sponsor's address:

264 Guangzhou Road, Gulou District, Nanjing City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京脑科医院

具体地址:

南京市鼓楼区广州路264号

Institution
hospital:

Nanjing Brain Hospital

Address:

264 Guangzhou Road, Gulou District, Nanjing City

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected project (self-funded)

Target disease:

Cerebral aneurysm

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

探究全身麻醉下颅脑动脉瘤介入栓塞手术后发生急性肾损伤(AKI)的危险因素,并构建临床预测模型,为临床防治提供依据,从而降低全身麻醉下颅脑动脉瘤介入栓塞手术后的AKI发生率  

Objectives of Study:

Investigate the risk factors for acute kidney injury (AKI) following endovascular embolization of intracranial aneurysms under general anesthesia, and develop a clinical prediction model to provide a basis for clinical prevention and treatment, thereby reducing the incidence of AKI after such procedures.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄18岁及以上; 2.在全身麻醉下接受颅脑动脉瘤介入栓塞手术

Inclusion criteria

1.Aged 18 years or older; 2.undergoing endovascular embolization for cerebral aneurysm under general anesthesia.

排除标准:

1.术前已出现急性肾损伤或因慢性肾衰竭需行肾脏替代治疗者; 2.术前使用肾毒性药物; 3.既往肾移植手术史; 4.临床资料缺失; 5.失访患者。

Exclusion criteria:

1.Acute renal injury before surgery or patients requiring renal replacement therapy due to chronic renal failure. 2.Use of nephrotoxic drugs before surgery. 3.History of kidney transplantation. 4.Missing clinical data. 5.Lost to follow-up patients.

研究实施时间:

Study execute time:

From 2024-09-01 00:00:00 To 2026-09-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-12-01 00:00:00 To 2026-09-01 00:00:00  

干预措施:

Interventions:

组别:

病例组

样本量:

500

Group:

cases

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China 

Province:

Jiangsu 

City:

 

单位(医院):

南京脑科医院 

单位级别:

三甲 

Institution
hospital:

Nanjing Brain Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

F1召回率

指标类型:

主要指标

Outcome:

F1 recall rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ROC曲线下面积

指标类型:

主要指标

Outcome:

Area under ROC curve

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

none

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

训练集数据来源于南京脑科医院电子病历系统以及手麻系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The training data comes from the electronic medical record system and the hand anesthesia system of Nanjing First Hospital.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2024-11-21 18:06:34